04/19/2026
The president just signed an Executive Order, specifically mentioning Ibogaine among therapeutic psychedelics to help those with serious mental illness, substance abuse and suicidal ideation.
Rumor has it. Ibogaine also has a cure(success) rate of 90% or so with he**in addicts...
The best outcomes will come from those using this plant medicine with the support/guidance of Holistic Psychotherapists, who are themselves versed in psychedelics.
What is Iboga/Ibogaine?
Iboga is a sacred plant medicine extracted from the root bark of a West African plant of the same name and has been used for centuries by indigenous cultures in ceremonial practices ranging from rites of passage to accessing past lives and ancestral trauma.
Some of the many potential benefits include:
Connecting with ancestors and finding personal meaning at the scale of the larger human experience.
Accessing universal truths about life and death that can give context to life, reduce depression, and relieve end-of-life anxiety.
Retrieving and navigating repressed memories and recovering from past grief.
Mitigating the addictive impulses of opioids, alcohol, narcotics, and other substance abuse and addictions, as well as reducing withdrawal symptoms.
Excerpts from the executive order:
"...Psychedelic drugs, including ibogaine compounds, show potential in clinical studies to address serious mental illnesses for patients whose conditions persist after completing standard therapy. Indeed, the Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to specific psychedelic drugs, and there are numerous products currently in the clinical trial pipeline for review of safety and efficacy. It is the policy of my Administration to accelerate innovative research models and appropriate drug approvals to increase access to psychedelic drugs that could save lives and reverse the crisis of serious mental illness in America.
Sec. 2. FDA Review Prioritization and Right to Try. (a) The Commissioner of Food and Drugs shall provide Commissioner’s National Priority Vouchers to appropriate psychedelic drugs that have received a Breakthrough Therapy designation and are in accordance with the criteria of the National Priority Voucher Program.
(b) The FDA and Drug Enforcement Administration shall facilitate and establish a pathway for eligible patients to access psychedelic drugs, including ibogaine compounds, under the Right to Try Act (21 U.S.C. 360bbb-0a), including any necessary Schedule I handling authorizations for treating physicians and researchers, consistent with 21 U.S.C. 823, and any applicable waiver authority under the Controlled Substances Act.
Sec. 3. Department of Health and Human Services Funding for Federal-State Collaboration. The Secretary of Health and Human Services shall, through the Advanced Research Projects Agency for Health, allocate at least $50 million from existing funds to support and partner with State governments that have enacted or are developing programs to advance psychedelic drugs for serious mental illnesses, including through Federal funding, technical assistance, and data sharing as appropriate and consistent with applicable law.
Sec. 4. Department of Health and Human Services and FDA Collaboration with the Department of Veterans Affairs and the Private Sector. The Department of Health and Human Services (HHS) and FDA shall collaborate with the Department of Veterans Affairs (VA) and, as appropriate and consistent with applicable law, including any privacy restrictions from the Privacy Act of 1974 and the Health Insurance Portability and Accountability Act of 1996, with the private sector, to increase clinical trial participation, data sharing, and real-world evidence generation regarding psychedelic drugs, and shall prioritize drugs that have received a Breakthrough Therapy designation. The HHS, FDA, and VA are directed to sign data-sharing memoranda as appropriate to ensure that data from relevant clinical studies conducted by other executive departments and agencies is made available to FDA to facilitate the timely evaluation and approval of drugs that meet standards for approval under section 505 of the Federal Food, Drug, and Cosmetic Act.
Sec. 5. Timely Rescheduling. The Attorney General shall, in consultation with HHS, initiate and complete review of any product containing a Schedule I substance that has successfully completed Phase 3 clinical trials for a serious mental health disorder, so that rescheduling, if appropriate under 21 U.S.C. 811, may proceed as quickly as practicable for such specific products that are ultimately approved under section 505 of the Federal Food, Drug, and Cosmetic Act..."
